GlassScriptPhysician profile
Jill Paulson
NPI 1346357936
$2,211.12
in general payments reported to CMS, 2019-2025
12 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $32.96 · 2021: $62.84 · 2022: $483 · 2023: $209 · 2024: $153 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $853.05 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Senseonics, Incorporated | $400.00 | 2022 | |
| Lilly USA, LLC | $383.55 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $247.97 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $124.80 | 2019 | |
| Beta Bionics, INC. | $40.31 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $35.30 | 2025 | Gvoke Hypopen |
| Roche Diabetes Care, INC. | $34.98 | 2021 | |
| Insulet Corporation | $32.16 | 2019-2025 | Omnipod |
| Cequr Corporation | $24.60 | 2025 | Cequr Simplicity |
| Amgen INC. | $19.30 | 2025 | Repatha |
| Abbott Laboratories | $15.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Paulson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.